Show simple item record

dc.contributor.authorRutherford, Ole-Christian Walter
dc.contributor.authorJonasson, Christian
dc.contributor.authorGhanima, Waleed Khalid
dc.contributor.authorHalvorsen, Sigrun
dc.identifier.citationEuropean Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 2020, 6 (2), 75–85en_US
dc.description.abstractThe aim of this study was to compare the risk of stroke or systemic embolism (SE) and major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and apixaban in routine clinical practice. Methods and results Using nationwide registries in Norway from January 2013 to December 2017, we established a cohort of 52 476 new users of non-vitamin K antagonist oral anticoagulants (NOACs) with AF. Users of individual NOACs were matched 1:1 on the propensity score to create three pairwise-matched cohorts: dabigatran vs. rivaroxaban (20 504 patients), dabigatran vs. apixaban (20 826 patients), and rivaroxaban vs. apixaban (27 398 patients). Hazard ratios (HRs) for the risk of stroke or SE and major bleeding were estimated. In the propensity-matched comparisons of the risk of stroke or SE, the HRs were 0.88 [95% confidence interval (CI) 0.76–1.02] for dabigatran vs. rivaroxaban, 0.88 (95% CI 0.75–1.02) for dabigatran vs. apixaban, and 1.00 (95% CI 0.89–1.14) for apixaban vs. rivaroxaban. For the risk of major bleeding, the HRs were 0.75 (95% CI 0.64–0.88) for dabigatran vs. rivaroxaban, 1.03 (95% CI 0.85–1.24) for dabigatran vs. apixaban, and 0.79 (95% CI 0.68–0.91) for apixaban vs. rivaroxaban. Conclusion In this nationwide study of patients with AF in Norway, we found no statistically significant differences in risk of stroke or SE in propensity-matched comparisons between dabigatran, rivaroxaban, and apixaban. However, dabigatran and apixaban were both associated with significantly lower risk of major bleeding compared with rivaroxaban.en_US
dc.publisherOxford University Press on behalf of the European Society of Cardiologyen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleComparison of dabigatran, rivaroxaban and apixaban for effectiveness and safety in atrial fibrillation; a nationwide cohort studyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.source.journalEuropean Heart Journal (EHJ) - Cardiovascular Pharmacotherapyen_US
dc.description.localcode© The Author(s) 2020. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal